Design and Dosage Form. Dr. Deny Susanti

Size: px
Start display at page:

Download "Design and Dosage Form. Dr. Deny Susanti"

Transcription

1 Design and Dosage Form Dr. Deny Susanti

2 Example 1 Aspirin tablet is stable but not as a liquid dosage form How to design liquid form? Soluble or dispersible aspirin tablets-to be dissolved in water Note: the resulting solution or suspension is to be taken immediately

3 Example 2 Benzylpenicillin is inactivated by gastric acid Susceptible to hydrolysis if stored as a solution How to administer to human? Formulated for parenteral, rather than for oral and packed as powder Use of sodium or potassium salt which readily dissolve upon reconstitution

4 Example 3 Diclofenac sodium is inactivated in gastric acid It is to be taken orally How to administer to human? Formulated for enteric coated tablet Enteric coat protects the tablet from destruction within the gastric chamber Enteric coated dissolves in the small intestine

5 Phase of Drug Development Preliminary pre-formulation Pre-formulation Early-stage development Late stage development Product Characterization-Physical and Chemical evaluations, early stage of pharmacology Formulation, Delivery, Packaging Development - Determination of dosage forms & Product formulation Pharmacokinetic and drug disposition, Preclinical Toxicity Testing-Pharmaceutical and in-vitro evaluation Clinical Trial-In-vivo and clinical evaluation Phase 1 Human Pharmacology-to evaluate the pharmacokinetic data and tolerance to healthy volunteers Phase 2-Therapeutic Exploratory-to evaluate a drug s preliminary efficacy and side effect in 100 to 250 patient Phase 3-Therapeutic Confirmatory-large scale clinical trial for safety and efficasy in large patient population

6 Pre-formulation The definition of preformulation proposed by Akers (1976): Preformulation testing encompasses all studies enacted on a new drug compound in order to produce useful information for subsequent formulation of a stable and biopharmaceutically suitable drug dosage form. Wells book on the subject (1988) Do not neglect these foundations. Good preformulation will inevitably lead to simple and elegant formulations and successful commercial products.

7 Pre-formulation Involves 3 main activities: Understanding physico-chemical parameter of a drug Characterization of drug molecule Application of biopharmaceutical principles An optimum drug delivery system Dosage forms

8 Physico-chemical parameters of a drug Characteristic-spectroscopy Solubility Melting point Cristallinity Particle size and particle size distribution Stability studies (in solid state and solution form) Excipient compatibility

9 Characteristic-Spectroscopy To confirm the drug structure and functional groups Usually by UV spectroscopy Info obtain also provide avenue to quantity the amount of drug in a particular solution (use wavelength at max) Other than UV spectroscopy: Infrared spectroscopy Nuclear magnetic resonance spectroscopy ( 1 H NMR and 13 C NMR) Mass spectrometry

10 Solubility Establishing solubility characteristics is valuable in developing a formulation and as a first step The solubility in various solvent is usually determined in a variety of commonly used solvent and water is the first choice For lipophilic drug molecule, some oil may be suitable Affects the bioavailability of the drug, the rate of drug release into the dissolution medium and consequently, the therapeutic efficacy of the pharmaceutical product.

11 Crystallinity Need to determine crystal morphology and particle size A polymorph is a solid material with two ore more different molecular arrangements and having a distinct crystal species. These difference disappear in the liquid or vapour state In general, the stable polymorph exhibits the highest melting point, the lowest solubility, and the maximum chemical stability

12 Structures of the polymorphs of estrone.

13 It is necessary that the preformulation protocol investigates and characterizes these phenomena so that: the desired forms can be consistently manufactured the effects of pharmaceutical manipulations are understood, e.g., granulation, milling and compression the effect of storage conditions on the dosage form can be evaluated and predicted, e.g., crystal growth in suspensions, creams and metered dose inhalers (MDIs) True polymorphs can be classified into two different types enantiotropic one polymorph can be reversibly changed into another one by varying the temperature or pressure. monotropic the change between the two forms is irreversible

14 Crystallinity Polymorphs generally have different melting points, x-ray diffraction patterns, and solubility, even though they are chemically identical Different dissolution rate > affect bioavailability Different tensile strength > compression ability Different stability at various temperature & pressure

15 Particle size, shape and surface area Various chemical and physical properties of drug substances are affected by their particle size distribution and shape Particle size is critical in the dose uniformity and dissolution rate of solid dosage form

16 Particle size, shape and surface area Poorly soluble drugs with low dissolution rate will be more readily bioavailable when administered in a finely subdivided states rather than as a coarse material Suspension and creams are more uniform if the ingredients used are in micronized form

17 Particle size and particle distribution Bulk flow, formulation homogeneity and surface area controlled processes such as dissolution and chemical reactivity are directly affected by size, shape & surface morphology of the drug particles as well as particle size distribution Size also be a factor in stability of tablets; fine materials are relatively more open to attack from atmospheric oxygen, the humidity, and interacting excipients than are coarse materials.

18 Chemical stability of active Max self-life allowable is 5 years Study of intrinsic stability of the active components allow better approaches to formulation, selection of a suitable materials and design of the packaging Include both solution and solid state experiments under conditions typical for the handling, formulation, storage, and administration of a drug candidate as well as stability in presence of other excipients

19 Chemical stability of active Critical factor affecting chemical stability in rational dosage form design include: Temperature & humidity ph, ionic strength Co-solvent, dosage form diluent Light Oxygen Stress condition utilized are: Elevated temperature studies Stability under high humidity conditions Photolytic stability Oxidative stability

20 Excipients Knowledge of drug-excipient interactions is therefore very useful to the formulator to enable selecting of suitable and appropriate excipients Excipients for a typical tablet contains binder, disintegrants, lubricants and fillers Excipients for a typical liquids contains preservatives, thickener, colorants, flavours, sweeteners, buffer and water The three techniques commonly employed in drug-excipient compatibility screening are: Thin layer chromatography Differential thermal analysis Diffuse reflectance spectroscopy

21 Drug-Excipient compatibility Drug No interaction 50% mixture DSC Recommend excipient Excipient Screening under nitrogen Interaction TLC Alternative excipient Yes Significant breakdown? No

22 Pre-formulation Involves 3 main activity: Understanding physico-chemical parameters of drug Characterization of drug molecule Application of biopharmaceutical principle An optimum drug delivery Dosage form

23 Pharmacology Study of the interaction of biologically active agents with living system (body) Pharmacodynamic- What the active agent does to the living body Pharmacokinetic (ADME)- What the body does to the active agent

24 Biopharmaceutics The study of the pharmaceutical factors which affect the fate of the drug after administration These factors need to be evaluated in the development of a new drug in order to determine the appropriate dose and dosage interval

25 Biopharmaceutics Influenced by the key interaction between the drug and the body after administration (ADME): Absorption (the way the drug enters the body and reaches the bloodstream) Distribution (where the drug goes in the body after it has been absorbed) Metabolism (how it is change by the body- e.g. in the liver) Elimination (the route by which it, or its metabolites, leave the body e.g. in the urine via the kidney)

26 Biopharmaceutics Different steps in the absorption process including the dissolution of the compound from the solid dosage form, interactions with the dissolved material in the gastro-intestinal lumen and the uptake of the compound through the epithelial membrane

27 Biopharmaceutics The biopharmaceutical information gathered in the candidate drug selection process regarding the characteristics of the drug molecule (e.g., dissolution, solubility, stability in fluids at the site of administration, enzymatic stability, membrane transport and bioavailability). This information is important for to determine suitable formulation types and technologies, to set biopharmaceutical targets for formulation development to define initial biopharmaceutical test methods and studies needed to reach the targets as background data for interpretation of different studies used in the development of a formulation.

28 Factor which influence drug absorption Physico-chemical properties of drug Lipophilicity of the drug Dosage form of drugs Rate of drug release from tablet or capsule formulations Some dosage forms purposely designed to slow down the dissolution rate of drug at a controlled rate rather than all at once. This is called sustained or controlled release

29 Factors which influence drug absorption Interaction with gastric juice For ph sensitive drugs Patient s age Newborn and geriatric are highly susceptible Patient s disease state Site of absorption of drugs Dose and dosage intervals Based on bioavailability study Drug-drug interaction As for food-drug interaction, this may retard or enhance drug absorption

30 Fate of Drug Upon administration of drug into the body, absorption need to happen before we can consider the fate of drug. Before absorption, the following must first take place: Release of drug from its dosage form into the biological fluids The release drug now in the biological fluids, will be dispersed and move to the absorption site (stomach, lung, skin, rectum, etc.)

31 Fate of Drug Next, the dissolved/released drug will move across the biological membranes (gastric linings, lung membranes, epidermis of skin, etc.) into the systemic circulation. This is called absorption Once absorbed, it will be distributed within the blood circulation During distribution, drug may bind reversibly to plasma or tissue proteins which act as storage depots in which the bound drug is in equilibrium with free drug in the tissue or plasma

32 Absorption Absorption via Passive Diffusion across GIT membrane Gastrointestinal fluid Gastrointestinal membrane Blood Drug in solution DIFFUSION Drug in solution carried away by circulating blood Partition Partition

33 Absorption Absorption via Active Transport across GIT membrane -for lipid-insoluble drugs, need a carrier (enzymes), one way flow Gastrointestinal fluid Gastrointestinal membrane Blood Drug + carrier Drug (in solution) Carrier Drug Carrier Drug in solution carried away by circulating blood Partition Partition

34 Fate of drug After absorption, drug will be metabolised ( e.g. in the liver), leading to: Inactivation of drug Formation of more polar, hydrophilic compounds which is more easily excreted and eliminated. Elimination rate depend on drug s half life Formation of an active moiety, where the original drug is inactive (Pro drug) Drug (as it or its metabolised form) will be excreted (via kidney, GIT, skin)

35 Half-life The biological half-life of a drug is used as a measure of how long the drug remains in the body It is the time required for the body to eliminate 50% of the drug which the body contained Shorter half-life drug requires more frequent dosage interval

36 Bioavailability The rate at which the amount of the administers dose of a drug is able to reach the systemic circulation

37 Bioavailability Assess by measuring drug concentration in a body fluid (often blood plasma) for a period of time after it has been administered Plot a graph showing drug plasma concentration against time after administration Indicate Therapeutic Range; between max. safe. Conc. (MSC) and min. effective conc. (MEC) given

38 Bioavailability Drug concentration drops below MEC prior to next dose. This is a bad dosage regimen (dose+interval) Higher initial dose improve bioavailability MSC : maximum safe concentration MEC: minimum effective concentration

39 Pre-formulation Involves 3 main acitivity: Understanding physico-chemical parameters of drug Characterization of drug molecule Application of biopharmaceutical principle An optimum drug delivery Dosage form

40 Why dosage form? Mechanism for the safe and convenient delivery of accurate dosage Protection of a drug substance from destructive influences of atmospheric oxygen or humidity Protection from influence of gastric acid after oral administration To mask taste of offensive drugs To provide liquid preparation of substances that are either insoluble or unstable To provide clear liquid dosage form To provide time-controlled release of drug To provide optimal topical administration To provide for the insertion of a drug into one of the body s orifices Provide for placement of drugs into the blood stream Provide for lung inhalation of drug

41 Dosage form To provide an optimum drug delivery

42 Dosage form At a certain stage during drug development, the dosage form of the drug (eg. a tablet, a capsule or an injection) has to be determined Although the formulator is concerned with the pharmaceutical aspect of drug design, there are many other factors that also determine which dosage form(s) is/are to be used. Amongst them are marketing considerations, equipment suitability, packaging requirements, target consumer groups, etc.

43 Dosage form Therapeutic consideration also play an important role in deciding the dosage form to use (eg. fast or slow onset required) Bioavailability not an issue for parenterals

44 Determination of Dosage Form Active not absorbed in GIT -> use as injection Active destroy by gastric juices -> as injection or enteric coated tablet Bronchodilators for fast action -> as inhaler powders or aerosol For long acting -> sustained released tablet For superficial problem -> use creams or ointments For slow release and long action -> controlled released cap/tab or transdermal patch

45 Common Dosage Forms Dosage form Tablets & capsules Injection & infusion Pessaries & suppositories Solution, suspension & elixir Ointments, & creams Aerosol & dry powder inhalation Transdermal patch Comment Convenient & commonest dosage forms but likely to be not good if the drug cannot be absorbed in the alimentary tract or if the patient (e.g. child) cannot swallow them Rapid action but impractical for treating chronic (long term) illness Can deliver the drug to local area where require but have limited general use Useful for children and the elderly but are bulky and less useful if the drug is unpalatable or unstable in the presence of water Use is restricted to topical application Good for drugs required in the lungs but can be difficult to administer the dose correctly Convenient if the dose needs to be released over a long period (eg.hormon replacement therapy) but can cause irritation

46 Benefits of pre-formulation studies Systemic way of drug development process Development of an effective, stable and safe drug product Allow development of an optimal design (dosage form) for administrators and users Avoid future drug or dosage related problems Avoid wastage of 4M resources (Man, machine, money, material)

Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs

Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs 1 Faculty of Pharmacy H-7624 Pécs, Rókus str.2. 2 Faculty of Pharmacy Department of Pharmacetical Biotechnology Department of

More information

The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form.

The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form. The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form. Three major needs that the formulation into a specific dosage form directly address

More information

Development of paediatric formulations - points to consider

Development of paediatric formulations - points to consider Development of paediatric formulations - points to consider Workshop on Paediatric Formulations II London, 8 November 2011 Presented by: Ann Marie Kaukonen Scientific Administrator, Paediatric Medicines,

More information

Howida Kamal, Ph.D. Ass. Prof. of Pharmaceutics, Cairo University

Howida Kamal, Ph.D. Ass. Prof. of Pharmaceutics, Cairo University Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University Dosage forms Sterile Free from all forms of microbial life (vegetative & sporing) Free from pathogens Non-sterile Extent of total bioburden

More information

Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza

Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza HorizonChem 2018, March, 6th 2018 1 Content Rottapharm Biotech : Company Overview Formulation

More information

Oral Delivery of Drugs

Oral Delivery of Drugs Oral Delivery of Drugs 1 S E S S I O N O N E O F T I P P R O J E C T Advantages of taking oral drugs Convenient (storage, portability, premeasured dose) economical non-invasive, often safer route requires

More information

Approval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D.

Approval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D. Approval Review of Generic Drugs Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D. Outline of Presentation Introduction Approval Review of Generic Drugs Equivalency review Conformity audit Conclusion

More information

Preformulation. By: Ass. Prof. Gamal Shazly

Preformulation. By: Ass. Prof. Gamal Shazly Preformulation By: Ass. Prof. Gamal Shazly Preformulation Testing It is the investigation of the physical and the chemical properties of the drug substance alone and when combined with formulating excipients

More information

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1 Institute of Pharmaceutical Technology and Biopharmacy University of Pécs 2017. szeptember 22. 1 Pre-discovery Goal: Understand the disease and choose a target molecule. How: Scientists in pharmaceutical

More information

Pharmaceutical Sciences

Pharmaceutical Sciences SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning

More information

Organic Pharmaceutical Chemistry: Prodrugs

Organic Pharmaceutical Chemistry: Prodrugs Organic Pharmaceutical Chemistry IV 1st Semester, Year 5 (2016-2017) Lecture 1 Organic Pharmaceutical Chemistry: Prodrugs Dr Asim A. Balakit Pharmaceutical Chemistry Dept., College of Pharmacy, Babylon

More information

INTRODUCTION TO PHARMACOLOGY

INTRODUCTION TO PHARMACOLOGY INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of

More information

Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal

Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC Contents

More information

The research work highlights the development and evaluation of. bioavailability of drugs. The buccal route can bypass the first-pass

The research work highlights the development and evaluation of. bioavailability of drugs. The buccal route can bypass the first-pass 212 9. Summary, conclusion and recommendation 9.1 Summary and conclusion The research work highlights the development and evaluation of novel transbuccal drug antagonist of Famotidine. route have a rapid

More information

PHARMACEUTICAL MANUFACTURING

PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL MANUFACTURING WHAT IS PHARMACEUTICAL MANUFACTURING IT IS THE PROCESS OF INDUSTRIAL SCALE SYNTHESIS OF PHARMACEUTICAL DRUG BY PHARMACEUTICAL COMPANIES. THE PROCESS CAN BE BROKEN DOWN INTO

More information

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics Biopharmaceutics Lecture :1 Module Introduction and Introduction to Biopharmaceutics Assist. Lecturer Ali Yaseen Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of

More information

Approaches to the formulation of poorly soluble drugs

Approaches to the formulation of poorly soluble drugs 1 Approaches to the formulation of poorly soluble drugs R. Christian Moreton, Ph.D FinnBrit Consulting ExcipientFest 2013, April 30 May 01, 2013, Baltimore, MD 2 Disclaimer The views expressed in this

More information

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug? Pharmacokinetics : Basic Principles verview 1. PK : Basic principles and processes 2. Important PK Parameters 3. Modulating PK Parameters 4. PK : Drugs vs. contrast agents Twan Lammers Dept. of Experimental

More information

Guidelines for Pharmaceutical Equivalence Requirements

Guidelines for Pharmaceutical Equivalence Requirements Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 1 September 2010 Page 1 of 9 Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 Drug Sector Saudi Food & Drug Authority

More information

Chimica Farmaceutica. Pharmacokinetics and related topics

Chimica Farmaceutica. Pharmacokinetics and related topics Chimica Farmaceutica Pharmacokinetics and related topics INTRODUCTION In order to produce its intended effect, a drug must be present at an appropriate concentration in the fluid surrounding the effect

More information

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D BY Mohammed Mahmoud Academic Session 147-8 1 st Semester (Semester No 71)

More information

RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products

RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August

More information

Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017

Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017 Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017 Biopharmaceutical Classification System Approximately 80% of drugs in the pharmaceutical compounds

More information

USP s Perspective on Drug Product Performance Test

USP s Perspective on Drug Product Performance Test USP s Perspective on Drug Product Performance Test Course Overview 1. The concept of in vitro dissolution Definition and application 2. Compendial dissolution/ drug release testing 3. Method development

More information

CHAPTER 1 PHARMACEUTICAL INDUSTRY

CHAPTER 1 PHARMACEUTICAL INDUSTRY 1 CHAPTER 1 PHARMACEUTICAL INDUSTRY 1.1 INTRODUCTION The global pharmaceutical industry, in the last few years, has been showing interest in India pharma industry because of its sustained economic growth,

More information

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997 Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products

More information

GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product

GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product Published by authority of the Minister of Health Date Adopted 2017/11/24 Effective Date 2017/11/24 Health Products

More information

Drug Delivery Systems. Joab Chen & Kenneth Tsang

Drug Delivery Systems. Joab Chen & Kenneth Tsang Drug Delivery Systems Joab Chen & Kenneth Tsang Drug Delivery How do we physically get drugs into our bodies? What are the various systems that are in use today? In the future? We as a class will determine

More information

Biopharmaceutics Applications in Drug Development

Biopharmaceutics Applications in Drug Development Biopharmaceutics Applications in Drug Development Edited by Rajesh Krishna Merck & Co., Inc. Rahwav, NJ. USA and Lawrence Yu Center for Drug Evaluation & Research Rockville, MD, USA 4y Springer Contents

More information

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability WHO Biowaiver Guideline in Regulatory Practice Dr Kamel IDDIR General Director Medicines and Pharmacy Directorate Berne

More information

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015 Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route

More information

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October

More information

WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability

WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability 2017 WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability Eric C Buxton Clinical Associate Professor University of Wisconsin Madison School of Pharmacy, Division of Pharmacy

More information

First UNGAP meeting Food-Drug Interactions Regulatory Aspects

First UNGAP meeting Food-Drug Interactions Regulatory Aspects First UNGAP meeting Food-Drug Interactions Regulatory Aspects Leuven, 09 March 2018 Dr. Henrike Potthast HPt COST meeting, Leuven, BE 09 March 2018 Page 1 Disclaimer The presentation reflects the personal

More information

DEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION

DEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION DEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION Guideline Title Development Pharmaceutics and Process Validation Legislative basis Directive 75/318/EEC as amended Date of first adoption April 1988 Date

More information

At LATITUDE, we only do one thing, and we do it very well.

At LATITUDE, we only do one thing, and we do it very well. Formulation Experts for Insoluble Compounds At LATITUDE, we only do one thing, and we do it very well. LATITUDE Pharmaceuticals Inc. has been tackling the most difficult drug formulation challenges for

More information

DRUG SOLUBILITY EXECUTIVE SUMMARY

DRUG SOLUBILITY EXECUTIVE SUMMARY DRUG SOLUBILITY Utilising a high throughput screening platform to determine the optimum pharmaceutical excipients in the development of liquid formulations EXECUTIVE SUMMARY Drugs are small molecules or

More information

CHAPTER INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES

CHAPTER INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES 1.0 INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES Oral ingestion is the preferred route for administration of therapeutic agents, providing a convenient method of effectively achieving both

More information

Course Curriculum for Master Degree in Pharmaceutical Technology

Course Curriculum for Master Degree in Pharmaceutical Technology Course Curriculum for Master Degree in Pharmaceutical Technology The Master Degree in Pharmaceutical Technology is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology

More information

Development of biopharmacy

Development of biopharmacy 31/10/2017 1 Development of biopharmacy Expression biopharmaceutics was composed By Gerhard Levy and it was written down by John G. Wagner in a publication from 1961 for the first time. Gerhard Levy Knowledge

More information

MODERN MEDICINAL CHEMISTRY

MODERN MEDICINAL CHEMISTRY MODERN MEDICINAL CHEMISTRY JOHN B. TAYLOR, B.SC.,D.I.C.,PI..D., Senior Vice President, Central Research, Rhone-Poulenc Rorer, Dagenham Research Centre, Essex and PETER D. KENNEWELL, B.A.,M.A.,Ph.D., Scientific

More information

Official Letter from the DOH

Official Letter from the DOH Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please

More information

PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS

PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS J. T. Carstensen, Ph.D. Professor of Pharmacy University of Wisconsin Madison, Wisconsin TECHNOMIC ^PUBLISHING CO.. INC J 1.ANCASTER BASET, TABLE OF CONTENTS

More information

BIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED BIOWAIVERS - M9

BIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED BIOWAIVERS - M9 BIOPHARMACEUTICS CLASSIFICATION - M9 Step 2 document to be released for comments Date 7 June 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Legal

More information

II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week THEORY

II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week THEORY II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week Solubility: Solubility of solid in liquids, Theory of solution formation. Solubilisation techniques using surfactants,

More information

Draft agreed by Pharmacokinetics Working Party February Adopted by CHMP for release for consultation 23 March 2017

Draft agreed by Pharmacokinetics Working Party February Adopted by CHMP for release for consultation 23 March 2017 18 October 2018 CPMP/EWP/239/95 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally

More information

Accelerating development of enabled formulations for poorly soluble drugs

Accelerating development of enabled formulations for poorly soluble drugs Accelerating development of enabled formulations for poorly soluble drugs John McDermott, Executive Director, Drug Product Optimisation Efficacy issues due to inadequate gastrointestinal (GI) absorption

More information

Hermes_highlights_need_for_better_formats_OTCBulletin_ pdf. Published July Accessed July 10, 2016.

Hermes_highlights_need_for_better_formats_OTCBulletin_ pdf. Published July Accessed July 10, 2016. Introduction An online survey conducted in the United States found that 50% of surveyed American adults (N = 1002) reported difficulty swallowing tablets and capsules. 1 These numbers are even higher in

More information

Formulation Development & CTM Manufacturing Services

Formulation Development & CTM Manufacturing Services Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range

More information

Liquisolid Compacts Based Orodispersible Tablets to Enhance Solubility of Atorvastatin using Experimental Design

Liquisolid Compacts Based Orodispersible Tablets to Enhance Solubility of Atorvastatin using Experimental Design Liquisolid Compacts Based Orodispersible Tablets to Enhance Solubility of Atorvastatin using Experimental Design Raj Shah 1 *, Hardeep Banwait 2, Sahjesh Rathi 2, Pragnesh Patni 3 1. Student of Master

More information

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase An Executive Summary From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase Leveraging knowledge about an API s physicochemical properties

More information

Excipient Development at NCL

Excipient Development at NCL New Reverse Enteric Polymer for Oral Dosage Forms Excipient Development at omplete Solution for Taste Masking Moisture Barrier Sustained Release Immediate Release Polymorphism Inhibition National hemical

More information

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2 Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has

More information

ADVANTAGES OF MULTIPARTICULATES (PELLETS):

ADVANTAGES OF MULTIPARTICULATES (PELLETS): INTRODUCTION: Multiparticulate Drug Delivery Systems (MDDS): The concept of multiple unit dosage form was initially introduced in the early 1950 s.these forms play a major role in the design of solid dosage

More information

Controlling drug delivery

Controlling drug delivery Sample chapter copyright Pharmaceutical Press www.pharmpress.com chapter 1 Controlling drug delivery Overview In this chapter we will: differentiate drug delivery systems according to their physical state

More information

TANZANIA FOOD AND DRUGS AUTHORITY

TANZANIA FOOD AND DRUGS AUTHORITY Doc. No. TFDA/DMC/MCER/---- TANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES ON THERAPEUTIC EQUIVALENCE REQUIREMENTS (Made under Section 52 (1) of the Tanzania Food, Drugs and Cosmetics Act, 2003) First Edition

More information

Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS. Lecture : 05. Practical : 04. Course Credit. Tutorial : 00.

Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS. Lecture : 05. Practical : 04. Course Credit. Tutorial : 00. Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS Course Code CT113 Lecture : 05 Course Credit Practical : 04 Tutorial : 00 Total : 09 Course Objectives Upon completion of course

More information

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS BASIC PHARMACOKINETICS AND PHARMACODYNAMICS An Integrated Textbook and Computer Simulations SARA ROSENBAUM ~ WILEY A lohn WILEY & SONS, INC., PUBLICATION CONTENTS Preface 1 Introduction to Pharmacokinetics

More information

INTER CHANGEABILITY and EQUIVALENCE. Where we are and what we still have to determine!

INTER CHANGEABILITY and EQUIVALENCE. Where we are and what we still have to determine! INTER CHANGEABILITY and EQUIVALENCE Where we are and what we still have to determine! Acknowledgement Joint presentation UNICEF/MSF/ICRC Cecile Mace Jean Michel Caudron Birgit Schmauser What do we mean

More information

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels

More information

FOOD AND DRUGS AUTHORITY

FOOD AND DRUGS AUTHORITY G H A N A FOOD AND DRUGS AUTHORITY GUIDELINES FOR STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS AND FINISHED PHARMACEUTICAL PRODUCTS Document No: FDA/DRI/DER/GL-STP/2013/07 Date of First Adoption:

More information

Line extension of immediate release products

Line extension of immediate release products EMA/EGA Joint Workshop on the Impact of the Revised EMA Guideline on Modified Release Dosage Forms Line extension of immediate release products London, 30 th April 2014 Dr. Alfredo García Arieta Jefe de

More information

Appendices! Product quality documents. Technical guidelines. (Translation from Original Chinese Version)

Appendices! Product quality documents. Technical guidelines. (Translation from Original Chinese Version) Appendices! (Translation from Original Chinese Version) Product quality documents Technical guidelines Appendix I General tests for various dose forms of pcms The general tests for various dose forms of

More information

Fig. 4. A two-compartment pharmacokinetic model.

Fig. 4. A two-compartment pharmacokinetic model. 3.4 Pharmacokinetic (PK) modeling and simulations Noora Sjöstedt, Wilma Kiander, Heidi Kidron 3.4.1 Introduction (Hanna Kortejärvi) Pharmacokinetic modeling and simulations can be performed with different

More information

In vivo predictive biopharmaceutics tools for oral drug delivery

In vivo predictive biopharmaceutics tools for oral drug delivery In vivo predictive biopharmaceutics tools for oral drug delivery Bertil Abrahamsson, AstraZeneca and Mark McAllister, Pfizer Background non-absorbable drug complex complex formation drug in solid dosage

More information

INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1

INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 LAB INSTRUCTORS: LECT. ANAS T ARIK NAFEA ASSIST. LECT. ZAINAB HASSAN MAHDI Definition of Industrial Pharmacy The conversion of raw materials into certain dosage

More information

Modern Pharmaceutics. Second Edition, Revised and Expanded. edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota

Modern Pharmaceutics. Second Edition, Revised and Expanded. edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota Modern Pharmaceutics Second Edition, Revised and Expanded edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota CHRISTOPHER T. RHODES : ' University of Rhode Island Kingston, Rhode

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/016/00-corr-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT

More information

Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish

Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish Annex 7 Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability 1 1. Introduction 134 2. Glossary 135 3. Documentation of equivalence for

More information

Antidotum Thallii-Heyl

Antidotum Thallii-Heyl SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT 500 mg hard capsules Active pharmaceutical ingredient: Ferric hexacyanoferrate(ii) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 hard

More information

Application of PBPK Models in Assessment of Bioequivalence

Application of PBPK Models in Assessment of Bioequivalence Application of PBPK Models in Assessment of Bioequivalence Robert Lionberger, Ph.D. Acting Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research, FDA

More information

Biowaiver Approaches for Generic Drug Products in the US: Case Studies

Biowaiver Approaches for Generic Drug Products in the US: Case Studies About OMICS Group OMICS Group is an amalgamation of Open Access Publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information

More information

GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)

GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs) GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs) DRAFT GUIDANCE This guidance document is for feedback purposes only Comments and suggestions regarding this draft document should be submitted within

More information

MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)

MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track) MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track) I. GENERAL RULES CONDITIONS: Plan Number 1 \ 12 70 2005 T 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of

More information

Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited

Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs Nikunjkumar Patel, Simcyp Limited IVIVC and Its Components CONVOLUTION VALIDATION DECONVOLUTION MODELS IVIVC

More information

Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development

Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality

More information

Experimental design on product development

Experimental design on product development Experimental design on product development Introduction What is the traditional developing method? What is experimental design? What do we need and what kind of possibilities do we have for designing?

More information

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables

More information

CLINICAL REQUIREMENTS FOR LOCALLY APPLIED, LOCALLY ACTING PRODUCTS, CONTAINING KNOWN CONSTITUENTS

CLINICAL REQUIREMENTS FOR LOCALLY APPLIED, LOCALLY ACTING PRODUCTS, CONTAINING KNOWN CONSTITUENTS CLINICAL REQUIREMENTS FOR LOCALLY APPLIED, LOCALLY ACTING PRODUCTS, CONTAINING KNOWN CONSTITUENTS Guideline Title Clinical Requirements for Locally Applied, Locally Acting Products, Containing Known Constituents

More information

Drug Development and Incrementally Modified Drugs : Regulatory Perspective. American Association of Pharmaceutical Scientists October 27, 2015

Drug Development and Incrementally Modified Drugs : Regulatory Perspective. American Association of Pharmaceutical Scientists October 27, 2015 Drug Development and Incrementally Modified Drugs : Regulatory Perspective American Association of Pharmaceutical Scientists October 27, 2015 Larissa Lapteva, M.D., M.H.S., Division of Therapeutic Performance

More information

Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1)

Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) 1 2 3 London, 21 February 2013 EMA/CHMP/EWP/280/96 Rev1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) 4 5 6 7 Guideline on the pharmacokinetic and clinical evaluation of modified release dosage

More information

SCF Particle generation in compliance with GMP

SCF Particle generation in compliance with GMP Abstract: SCF Particle generation in compliance with GMP Michel PERRUT, Frantz DESCHAMPS, Jennifer JUNG, Fabrice LEBOEUF SEPAREX F-54250 Champigneulles France mperrut@separex.fr Fax : + 33 383 31 24 83

More information

Adare Pharmaceuticals. A partnership that adds value to your products

Adare Pharmaceuticals. A partnership that adds value to your products Adare Pharmaceuticals Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health. Our vision to expand Building upon our legacy, we strive to reshape medicines

More information

PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS

PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS RADIOPHARMACEUTICALS Guideline Title Radiopharmaceuticals Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC Date of first adoption December 1990 Date of entry into June

More information

Research Article Pharmaceutical Sciences

Research Article Pharmaceutical Sciences Page185 Research Article Pharmaceutical Sciences ENHANCEMENT OF DISSOLUTION RATE OF EFAVIRENZ BY SOLID DISPERSION TECHNIQUE B. Venkateswara Reddy 1*, K.V. Ramana Murthy 2 1* Department of Pharmaceutics,

More information

The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G

The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G (1) INTRODUCTION The following guideline defines the stability data package for a drug

More information

Injectable modified release products

Injectable modified release products Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the

More information

STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS

STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS

More information

How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER

How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco

More information

Formulation and in vitro evaluation of bosentan osmatic controlled release tablets

Formulation and in vitro evaluation of bosentan osmatic controlled release tablets IJPAR Vol.4 Issue 4 Oct- Dec -2015 Journal Home page: ISSN: 2320-2831 Research article Open Access Formulation and in vitro evaluation of bosentan osmatic controlled release tablets Mohammed Asif Hussain,

More information

Physical pharmacy. dr basam al zayady

Physical pharmacy. dr basam al zayady Physical pharmacy Lec 5 dr basam al zayady Liquefaction of Gases: When a gas is cooled, it loses some of its kinetic energy in the form of heat, and the velocity of the molecules decreases. If pressure

More information

Performance Testing of Novel Dosage Forms

Performance Testing of Novel Dosage Forms RQA Ireland Regional Forum - Athlone, May 2016 Quality Considerations Pharma and Biopharma Performance Testing of Novel Dosage Forms Terry Way BPharm MAPS Dissolution Science Consultant Glasside Technologies

More information

Model based approaches to target special populations with rational formulation and clinical design strategies

Model based approaches to target special populations with rational formulation and clinical design strategies Model based approaches to target special populations with rational formulation and clinical design strategies David Good 3 rd FDA/PQRI Conference on Advancing Product Quality Modeling for Oral and Non-Oral

More information

Natural Products and Drug Discovery

Natural Products and Drug Discovery Natural Products and Drug Discovery Secondary metabolism Building blocks & Phytochemicals Drug discovery 26-Oct-18 2 Secondary metabolism: Biochemical reactions derived from primary metabolic pathways

More information

CHAPTER 8: SOLID DOSAGE FORM COATING TECHNOLOGY NOOR MUHAMMAD SYAHRIN BIN YAHYA INTRODUCTION

CHAPTER 8: SOLID DOSAGE FORM COATING TECHNOLOGY NOOR MUHAMMAD SYAHRIN BIN YAHYA INTRODUCTION CHAPTER 8: SOLID DOSAGE FORM COATING TECHNOLOGY NOOR MUHAMMAD SYAHRIN BIN YAHYA INTRODUCTION INTRODUCTION Coating technology is used extensively in the pharmaceutical industry, e.g. for the application

More information

Biovailability and stability of erythromycin delayed release tablets

Biovailability and stability of erythromycin delayed release tablets Biovailability and stability of erythromycin delayed release tablets 1 Sydney Ogwal* and 2 Xide T.U 1 Department of pharmacy, Faculty of Medicine, Makerere University P. O. Box 7072 Kampala Uganda 2 Department

More information

Biology 137 Introduction to Toxicology Fall Which of the following would enhance the excretion of xenobiotic molecules?

Biology 137 Introduction to Toxicology Fall Which of the following would enhance the excretion of xenobiotic molecules? 1. Which of the following would enhance the excretion of xenobiotic molecules? A) removal of hydroxyl groups and replacement with hydrogen B) increased hydrophobicity of the molecule, which would allow

More information

Warfarin suspension. Group B Presentation

Warfarin suspension. Group B Presentation Warfarin suspension 200mcg/ml Group B Presentation Group B - members Lene, Denmark Nihal, Turkey Jaldaz, FYROM, Mark, UK Matjaz, Slovenia Vincentas, Lithuania Juraj, Slovakia Our Business Provide service

More information

USE OF SPHERICAL TECHNOLOGIES

USE OF SPHERICAL TECHNOLOGIES USE OF SPHERICAL TECHNOLOGIES USE OF SPHERICAL TECHNIQUES Spherical techniques are widely used to make particles spherical since spherical shape possesses properties suitable for their easy manufacturing.

More information

Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances

Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry U.S. Department of Health and Human

More information